首页|基于LCK募集和活化的嵌合抗原受体T细胞的结构优化及其功能研究

基于LCK募集和活化的嵌合抗原受体T细胞的结构优化及其功能研究

扫码查看
目的 通过对二代嵌合抗原受体(CAR)进行淋巴细胞特异蛋白酪氨酸激酶(LCK)结构改造,探讨能否增强二代CD137 CAR-T细胞的活化水平及杀伤肿瘤细胞效率,为制备新型二代CAR-T细胞奠定基础。方法 利用基因工程技术,构建靶向人表皮生长因子受体-2(HER2)的CD137-LCK2 CAR和CD137-PYAP2 CAR的慢病毒载体,经慢病毒包装、感染活化T细胞后制备出CD137-LCK2和CD137-PYAP2 CAR-T细胞。采用流式细胞术、酶联免疫吸附实验、细胞毒性实验分别检测新构建的CAR-T细胞在活化分子CD137的表达水平、表型分布、分泌的细胞因子水平及对表达HER2的肿瘤细胞的杀伤效率。结果 相较于二代CD137 CAR-T细胞,经过结构改造的靶向HER2的CD137-LCK2和CD137-PYAP2 CAR-T细胞能够上调活化分子CD137的表达、增加细胞因子IFN-γ的分泌、增强对靶细胞的杀伤能力,且均有统计学差异;同时能够维持在记忆状态、受抗原刺激后可迅速活化增殖分化。结论 靶向HER2的CD137-LCK2和CD137-PYAP2 CAR-T细胞有望比二代CD137 CAR-T细胞能更有效活化并发挥抗肿瘤效应。
Structure optimization and function evaluation of chimeric antigen receptor T cells based on LCK recruitment and activation
This study aims to enhance the activation level and efficiency of second-generation chimeric antigen receptor-T(CAR-T)cells in killing tumor cells by modifying the lymphocyte-specific protein tyrosine kinase(LCK)structure of second-generation CAR,so as to lay the foundation for the preparation of novel second-generation CAR-T cells.Using genetic engineering techniques,lentiviral vectors for CD137-LCK2 CAR and CD137-PYAP2 CAR targeting human epidermal growth factor receptor 2(HER2)were constructed,and CD137-LCK2 and CD137-PYAP2 CAR-T cells were prepared by lentiviral packaging and infection of activated T cells.The differences between them in terms of CAR expression level,activating molecule CD 137 expression,phenotypic distribution,cytokines secretion,and killing effect on HER2-expressing tumor cells were detected and compared using flow cytometry,enzyme-linked immunosorbent assay,and cytotoxicity assay,respectively.Compared with the second-generation CD137 CAR-T cells,the structurally modified CD137-LCK2 and CD137-PYAP2 CAR-T cells targeting HER2 can increase the expression of activating molecule CD 137,increase the secretion of cytokine IFN-γ,and enhance the killing ability of target antigens;at the same time,these cells can be maintained in the memory state and can rapidly activate proliferation and differentiation after stimulation by antigen.In conclusion,CD137-LCK2 and CD137-PYAP2 CAR-T cells targeting HER2 are expected to activate and exert anti-tumor effects more effectively than second-generation CD 137 CAR-T cells.

Chimeric antigen receptor T cellLymphocyte-specific protein tyrosine kinaseCytotoxicity

邹琳、陈思吟、杜丽、陶崑

展开 >

400016,重庆医科大学基础医学院免疫学教研室

400016,肿瘤免疫基础与转化研究重庆市重点实验室

400016,重庆医科大学附属第一医院临床分子医学检测中心

嵌合抗原受体T细胞 淋巴细胞特异性蛋白酪氨酸激酶 细胞毒性

2024

免疫学杂志
第三军医大学,中国免疫学会

免疫学杂志

CSTPCD
影响因子:0.704
ISSN:1000-8861
年,卷(期):2024.40(1)
  • 1